Vera Therapeutics, Inc. Q3 2026 Earnings Recap

Vera’s shares fell 1.2% after earnings, a roughly flat reaction. The quarter featured an early U.S. launch and positive ORIGIN 3 data, while the company is still pursuing full approval and did not provide launch revenue figures in the remarks.

Key Takeaways

• Since the July 7 accelerated approval, Vera has received approximately 700 patient start forms for TRUTAKNA; management said it expects net product revenue to become a primary progress indicator alongside start forms.
• In ORIGIN 3, the placebo-adjusted eGFR change at 52 weeks was 5.6 mL/min: eGFR was −0.1 with TRUTAKNA versus −5.7 with placebo.
• Through 104 weeks, the placebo-adjusted annualized eGFR slope was 5.0 mL/min/year; TRUTAKNA’s slope was −0.6 versus −5.6 with placebo. The treatment reduced the risk of the composite kidney disease progression endpoint by 76% (hazard ratio 0.24).
• Vera submitted a supplemental biologics license application seeking full FDA approval and is targeting a first-quarter 2027 European marketing authorization application, with potential U.S. full approval in mid-2027.
• The company is also advancing the Phase II PIONEER basket trial and a once-monthly dose-range-finding study to explore atacicept in broader patient populations.